First, although Low et al. demonstrated effective activation of the cGAS–STING pathway by decitabine treatment in cell lines, many potential immunotherapies seemed to fail in clinical trials in GBM later on, with few patients showing durable responses.4 The DNA incorporating functional feature of DNMTis make them advantageous in targeting the rapidly dividing cells, which is the case for cultured cell lines. The gene discussed is CGAS; the disease is glioblastoma.